Second-Generation Antidepressants for Treating Adult Depression—An Update
Overall Comparative Harms of Second-Generation Antidepressants for Adults With Major Depressive Disorder
Overall there is high-strength evidence that the rates of adverse events were similar among second-generation antidepressants, though incidence of specific adverse effects differed across antidepressants and will be addressed in the following slides. Research on comparative harms for the different formulations of second-generation antidepressants found that there was moderate-strength evidence that there were no differences in harms between fluoxetine daily and fluoxetine weekly or between venlafaxine immediate release and venlafaxine extended release.
- Gartlehner G, Hansen RA, Morgan LC, et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Comparative Effectiveness Review No. 46 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; December 2011. AHRQ Publication No. 12-EHC012-EF. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.
Your slide tray is being processed.